BioLineRx to Report First Quarter 2025 Results on May 27, 2025

Rhea-AI Summary

BioLineRx (NASDAQ: BLRX), a development stage biopharmaceutical company focused on oncology and rare diseases, has scheduled the release of its Q1 2025 unaudited financial results for May 27, 2025, before U.S. markets open. The company will host a conference call at 8:30 a.m. EDT featuring CEO Philip Serlin.

Investors can access the call via U.S. dial-in (+1-888-281-1167) or international dial-in (+972-3-918-0685). A live webcast and replay will be available through the company's website, with a dial-in replay accessible until May 29, 2024.

News Market Reaction – BLRX

+11.34%

1 alert

+11.34% News Effect

On the day this news was published, BLRX gained 11.34%, reflecting a significant positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Management to Hold Conference Call at 8:30 a.m. EDT

TEL AVIV, Israel, May 20, 2025 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it will release its unaudited financial results for the quarter ended March 31, 2025 on Tuesday, May 27, 2025, before the U.S. markets open.

The Company will host a conference call at 8:30 a.m. EDT featuring remarks by Philip Serlin, Chief Executive Officer.

To access the conference call, please dial +1-888-281-1167 from the U.S. or +972-3-918-0685 internationally. A live webcast and a replay of the call can be accessed through the event page on the Company's website. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast. The call replay will be available approximately two hours after completion of the live conference call. A dial-in replay of the call will be available until May 29, 2024; please dial +1-888-295-2634 from the US or +972-3-925-5904 internationally.

About BioLineRx

BioLineRx Ltd. (NASDAQ/TASE: BLRX) is a biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases. The Company's first approved product is APHEXDA® (motixafortide), with an indication in the U.S. for stem cell mobilization for autologous transplantation in multiple myeloma, which is being developed and commercialized by Ayrmid Ltd. (globally, excluding Asia) and Gloria Biosciences (in Asia). BioLineRx is utilizing its end-to-end expertise in development, regulatory affairs, manufacturing and commercialization to advance its innovative pipeline and ensure life-changing discoveries move beyond the bench to the bedside.

Learn more about who we are, what we do, and how we do it at www.biolinerx.com, or on Twitter and LinkedIn.  and events.

Logo: https://mma.prnewswire.com/media/2154863/BioLineRx_Ltd_Logo.jpg

Contacts:

United States
Irina Koffler
LifeSci Advisors, LLC
IR@biolinerx.com

Israel
Moran Meir
LifeSci Advisors, LLC
moran@lifesciadvisors.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/biolinerx-to-report-first-quarter-2025-results-on-may-27-2025-302460229.html

SOURCE BioLineRx Ltd.

FAQ

When will BioLineRx (BLRX) report its Q1 2025 earnings?

BioLineRx will report its Q1 2025 earnings on Tuesday, May 27, 2025, before U.S. markets open.

What time is the BioLineRx (BLRX) Q1 2025 earnings conference call?

The earnings conference call is scheduled for 8:30 a.m. EDT on May 27, 2025.

How can I access BioLineRx's (BLRX) Q1 2025 earnings call?

You can access the call by dialing +1-888-281-1167 (U.S.) or +972-3-918-0685 (international), or through the live webcast available on the company's website.

Who will be speaking at BioLineRx's Q1 2025 earnings call?

Philip Serlin, BioLineRx's Chief Executive Officer, will be featured on the earnings call.